e538 Journal of Hypertension

PP.32.293

Vol 28, e-Supplement A, June 2010

PREGNANCY AND ANTIHYPERTENSIVE DRUGS

M. Leppee1, J. Culig1, N. Colak2, M. Eric3. 1Andrija Stampar Institute of

Public Health Zagreb, Zagreb, Croatia, 2Colpharm Doo, Siroki Brijeg, Bosnia
Herzegovina, 3Medical School Novi Sad, Novi Sad, Serbia
The aim of the study was to assess the prevalence of antihypertensive drug
use and the rate of congenital malformations in neonates at in utero exposure
to these drugs. The study was performed at departments of gynecology and
obstetrics in four medical institutions in Zagreb and was conducted by use of
a simply structured standardized questionnaire that consisted of two parts:
mothers interview and hospital records. The epidemiological study involved
893 pregnant women. At least one drug was used during pregnancy and early
postpartum period by 96,2% of 893 study women, with a mean of 2,7 drugs
per woman. During the first trimester of gestation, which is most important
for fetal development, drugs were taken by 859 (96.2%) women. Relatively
large number of women used atenolol during pregnancy (a total of 82 or
9.2%); before pregnancy it took seven women, in the first trimester 17
pregnant women, in the second 32 and in third 62 pregnant women, which
indicates that the number of pregnant women taking this medicine increased
in parallel with the duration of pregnancy. According to FDA classification
atenolol belongs to category D. Among the women who have birth children
with heart and blood vessels malformations, one have taken atenolol during
the entire pregnancy. It is a negligible percentage of impressions malformations and can not relate taking atenolol with the emergence of malformations of the heart and blood vessels. Calcium channel blockers verapamil
have been taken one woman in the first, 11 in the second and 17 in the third
trimester. Nifedipine have used negligible number of women (three in the
first, two in the second and four in the third trimester). Eight women have
been used ACE inhibitors (lisinopril four, cilazapril and enalapril two).
Accordingly, the use of ATC group C agents increases with pregnancy
advancement, as also indicated by our results. The usage of the most
common used antihypertesive drugs, assume to be safe during lactation.

PP.32.294

GESTATIONAL HYPERTENSION: RISK FACTORS,

CLINICAL AND LABORATORY FINDINGS

A. Molina Ordas1, A. Rodriguez Gomez, M. Heras Benito, M.J. FernandezReyes Luis, R. Sanchez Hernandez, F. Alvarez-Ude Cotera. 1Hospital
General de Segovia, Segovia, Spain
Gestational hypertension is not an uncommon situation. Previous studies
have shown up hypertensive disorders complicate 5 to 10 percent of
pregnancies. Multiple risk factors in gestational hypertension development have been described, just as: previous obstetrical preeclampsia
history, first pregnancy, age, hypertension family history, obesity, multiple
gestation. . . We have collected all gestational hypertension cases and its
clinical and laboratory findings from our hospital between 1st January 2003
and 31st December 2009. We have evaluated 46 women. As a result of, we
have found out the hypertension beginning was of 24.02 / 12.36 weeks.
The gestation ending was of 36.65 / 2.70 weeks [5% women by
caesarean section]. 15 women [32.6%] had developed hypertension in
previous pregnancy and 17 [37%] had hypertension familiar history. Only 6
women [15.9%] were diabetic or had developed gestational diabetes. The
most frequent antihypertensive treatment was Captopril [85.4%] followed
by nifedipine [34,8%], labetalol [30.4%], and methyldopa [15.2%]. The
most frequent laboratory findings were low levels of albumin [3.18 /
0.53], proteinuria [1.20 / 1.82] and a rise level in LDH [520.65 /
408], uric [6.02 / 1.7], and AST [44.13 / 87.36], ALT [44.35 /
72.06]. Hypertension familiar history patients have a bigger proteinuria
[p 0.06]. It was more frequent the hypertension development of a
previous gestation [p 0.024] and hypertension beginning after gestation
[p 0.014]. The gestational hypertension beginning was earlier in women
with a previous pregnancy hypertension history [p 0.001]. Finally,
patients who required methyldopa treatment ended their pregnancy
before the others [p 0.039].